HOME >> MEDICINE >> NEWS
Treatment-Resistant Depression: Results of Latest Electromagnetic Stimulation Study Show Promise

eters below the brain's surface. Unlike ECT for depression, rTMS does not require anesthesia or analgesics."

Study subjects were antidepressant-free for one week prior to rTMS and received 10 daily treatments (10 trains of five seconds each, 25 seconds apart) at a frequency of 10 Hz. Seventy-eight percent of patients experienced mild-moderate discomfort at the site of stimulation, two patients who experienced severe pain in the treatment site dropped out of the study and eight percent of patients experienced a posttreatment headache.

The mean age of patients treated was 52 years. " rTMS seems most promising for older adults and for treatment-resistant patients with depression," says Dr. McDonald, who directs the Fuqua Center for Late-Life Depression at Wesley Woods.

Also collarborating on the study were Charles M. Epstein, M.D., associate professor of neurology at Emory; Liquong He, M.D., formerly with Emory; Autumn L. Clark, B.S., study coordinator in Emory's department of psychiatry and behavioral sciences; Fred A. Marstellar, Ph.D., associate professor of psychiatry and behavioral sciences at Emory; and John Woodard, Ph.D., of the Georgia State University Memory Assessment Clinic.

The study was supported by a private grant from the Fuqua Foundation.


'"/>

Contact: Sarah Goodwin
sgoodwi@emory@emory.edu
404-727-3366
Emory University Health Sciences Center
17-May-1999


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
9. Results of NUVANCE phase I/II asthma trial presented
10. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
11. UI Study Yields Encouraging Results For New Breast Cancer Treatment

Post Your Comments:
(Date:5/20/2013)... VHA Inc., the national health care ... population health improvement, announced a new offering to ... pursue population health management with a strategic ... the transition to value-based models of care. As ... of services, the offering integrates VHA expert advisory ...
(Date:5/20/2013)... have mapped the significance of heredity for common ... examined whether different forms of the disease share ... ischemic stroke, peripheral arterial disease and atherosclerosis of ... have suffered different types of cardiovascular disease. , ... atherosclerosis of the aorta followed by peripheral arterial ...
(Date:5/20/2013)... Gilman Law LLP, a leading pharmacy ... lawsuits, is troubled by a new study that reveals ... type 2 diabetes drugs are growing. The analysis, ... found that 71 Byetta pancreatic cancer reports had been ... as of June 30, 2012. Overall, Byetta ...
(Date:5/20/2013)... Newport News, VA (PRWEB) May 20, 2013 ... Jeffrey Carlson successfully performed a procedure using SpineFrontier’s FacetFuse ... Fusion Device System. The operation took place on ... Hospital in Newport News, VA. The surgery was ... a 66 year-old, female patient. , Dr. Carlson described ...
(Date:5/20/2013)... The study comprised over 24,000 Finnish subjects and ... revealed that a panel of 28 genetic markers ... coronary heart disease (CHD) (10-year risk ≥20%) over ... is an important preventive strategy for CHD, because ... high-risk group. "The results indicate that genetic markers ...
Breaking Medicine News(10 mins):Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3Health News:Dr. Jeffrey Carlson Successfully Performs Procedure Using SpineFrontier’s Less Exposure Surgery Technology: FacetFuse 2Health News:Dr. Jeffrey Carlson Successfully Performs Procedure Using SpineFrontier’s Less Exposure Surgery Technology: FacetFuse 3
(Date:5/17/2013)... 17, 2013 Medical devices are any medical ... product. In light of their different mechanisms, actions and ... more complicated than drug trails due to their unique ... instead of evaluating both safety and efficacy (which is ... is the same as the SFDA) evaluate MDs for ...
(Date:5/17/2013)... DIEGO , May 17, 2013  Sorrento ... that its Fast-Track Advanced Technology Small Business Technology ... Institute of Allergy and Infectious Diseases (NIAID), a ... supporting the development of novel human antibody therapeutics ... aureus or Staph) infections, including methicillin-resistant ...
(Date:5/17/2013)... , May 17, 2013  Technology advances ... communicate internally. Faced with a constantly evolving communication ... and tactics for communicating with internal executives. It ... all the strategies, tactics and tools that are ... In a new study, Best Practices, LLC explores ...
Breaking Medicine Technology:Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2
Cached News: